(E)-3-(6-bromopyridin-2-yl)-2-cyano-N-((1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl)acrylamide | 951693-94-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-((1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl)acrylamide
• 英文别名: (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]prop-2-enamide
• CAS: 951693-94-0
• 化学式: C₁₈H₁₄BrN₃O₂
• 分子量: 384.232
• InChiKey: AOOPSMWAONDSSY-XUMBHXRASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  86
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Orally Bioavailable Caffeic Acid Related Anticancer Drugs
  申请人：Priebe Waldemar

  公开号：US20070232668A1

  公开（公告）日：2007-10-04

  The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.

  本发明涉及化合物及其用于治疗细胞增殖性疾病如癌症的用途。本发明的化合物作为Jak2/STAT3途径和下游靶点的抑制剂显示出显著的效力，并抑制癌细胞系的生长和存活。
• ORALLY BIOAVAILABLE CAFFEIC ACID RELATED ANTICANCER DRUGS
  申请人：The Board of Regents of the University of Texas System

  公开号：US20150094343A1

  公开（公告）日：2015-04-02

  The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.

  本发明涉及化合物及其用于治疗细胞增殖性疾病，例如癌症。本发明的化合物作为Jak2 / STAT3途径及下游靶点的抑制剂具有显著的效力，并抑制癌细胞系的生长和存活。
• TRYPHOSTIN-ANALOGS FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES
  申请人：Donato Nicholas J

  公开号：US20100292229A1

  公开（公告）日：2010-11-18

  The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. In general aspects, compounds of the present invention are tyrphostin-like in structure. Compounds of the present invention, in certain embodiments, display significant potency by causing, for example, inhibition of Stat3 activation, reduction in c-myc protein levels and/or induction of apoptosis in tumor cells. In general aspects, compounds of the present invention induce one or more of these activities at nanomolar concentrations and typically function through a unique mechanism involving the induction of stress granules that bind specific signaling molecules and prevent them from participating in signal transduction and oncogenesis.

  本发明涉及化合物及其用于治疗细胞增殖性疾病，如癌症。在一般方面，本发明的化合物在结构上类似于酪氨酸激酶抑制剂。在某些实施例中，本发明的化合物通过诱导应激颗粒结合特定信号分子并阻止它们参与信号转导和肿瘤发生，从而表现出显著的效力，例如抑制Stat3激活、降低c-myc蛋白水平和/或诱导肿瘤细胞凋亡。在一般方面，本发明的化合物在纳摩尔浓度下诱导这些活性中的一个或多个，并通常通过诱导应激颗粒的独特机制发挥作用，这些应激颗粒结合特定信号分子并防止它们参与信号转导和肿瘤发生。
• Orally bioavailable cafeic acid related anticancer drugs
  申请人：The Board of Regents of The University of Texas System

  公开号：EP2514742A2

  公开（公告）日：2012-10-24

  The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as inhibitors of Jak2/STAT3 pathways and downstream targets and inhibit the growth and survival of cancerous cell lines.

  本发明涉及化合物及其用于治疗癌症等细胞增殖性疾病。本发明的化合物作为 Jak2/STAT3 通路和下游靶点的抑制剂具有显著的效力，可抑制癌细胞株的生长和存活。
• Methods of Treating Skin Disorders with Caffeic Acid Analogs
  申请人：Priebe Waldemar

  公开号：US20100152143A1

  公开（公告）日：2010-06-17

  Embodiments of the invention generally relate to pharmaceutical compositions containing at least one caffeic acid compound and methods for the topical treatment of proliferative and inflammatory skin disorders such as plaque psoriasis, atopic dermatitis, and other disorders. In some embodiments, the topical treatment includes applications of the pharmaceutical composition containing at least one caffeic acid compound or a mixture of caffeic acid compounds such as caffeic acid ester compounds, caffeic acid amide compounds, analogues thereof, derivatives thereof, salts thereof, or mixtures thereof. The pharmaceutical composition or topical dosage may contain the caffeic acid compound at a concentration by weight within a range from about 0.01% to about 20%, preferably, from about 0.1% to about 15%, preferably, from about 1% to about 10%, more preferably, from about 3% to about 7%, and more preferably, from about 4% to about 6%.